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Abstract 
Adverse reactions to N-acetylcysteine are reported in 6% to 23% of patients who are administered the 
antidote for treatment of paracetamol poisoning.1 Because paracetamol is the most common 
pharmaceutical product taken in overdose in many countries, it is essential that attempts be made to 
prevent or minimize adverse effects caused by N-acetylcysteine. We congratulate Kerr et al2 on their 
attempt to address this important issue. 
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To the Editor: 
 
Adverse reactions to N-acetylcysteine are reported in 6% to 23% of patients who are 
administered the antidote for treatment of paracetamol poisoning.1 Because paracetamol is 
the most common pharmaceutical product taken in overdose in many countries, it is 
essential that attempts be made to prevent or minimize adverse effects caused by  
N-acetylcysteine. We congratulate Kerr et al2 on their attempt to address this important 
issue. 
We would like to comment on the following. 
Previous studies have shown that atopic individuals, and particularly asthmatic 
individuals, are more likely to develop reactions to N-acetylcysteine.3 We do not know from 
the study how many individuals in this study were atopic or asthmatic. The incidence of 
asthma in Australia is recognized to be amongst the highest in world.4 
Adverse reactions to N-acetylcysteine are more prevalent with low concentrations of 
paracetamol in the blood of the patient being treated.3 Analysis of this risk factor for 
anaphylactoid reactions would have been helpful in the study. The reactions to  
N-acetylcysteine would also depend on the plasma N-acetylcysteine concentration,5 which 
was not estimated in this study. A further reason for determining plasma N-acetylcysteine 
concentrations is that previous studies have shown that there are often large variations in 
the dose of N-acetylcysteine to patients with paracetamol poisoning caused 
by administration errors.6 
The endpoints measured in the study comprise various adverse events as recorded 
by the treating physician. Yet classification of the reaction and whether the reaction was 
drug related or not was decided independently by 2 investigators at a later date. The 
potential ‘‘subjective’’ nature of this assessment is a possible source of bias. Actions taken 
to treat an event have been taken into account when such classification was made. It is not 
unusual for different physicians to treat the same condition differently. Furthermore, the 
classification system used was one designed for adverse events associated with long-term 
drug administration. 
The best indicator of hepatotoxicity caused by paracetamol is International 
Normalized Ratio (INR). Though measurement of alanine amino transferase (ALT) and INR 
was made, maximum measured values of ALT were used to assess the efficacy of the 2 
treatment arms. The baseline ALT concentration has a bearing on the maximum level 
reached, and therefore the degree of increase in ALT from baseline might 
have been a better indicator. 
N-acetylcysteine has an elimination half-life of 5.7 hours. Adverse events were 
observed every 30 minutes during the first 4 hours and at 2-, 4-, and 8-hour intervals 
subsequently. Given a half-life of almost 6 hours, the results may have been different if the 
observations had been made more frequently, especially in the early part of the infusion. It 
would have been helpful if the adverse events after the first 15 minutes were compared 
between the 2 groups because most adverse reactions seem to occur during the first 15 
minutes.5 
The study on N-acetylcysteine use and infusion rates probably needs to be repeated 
over a long loading time and with detailed study of adverse events. 
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